secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001437749-25-025814
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase
--------------------------------------------------------------------------------

- Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.
- Phase 2b RewinD-LB extension: neflamapimod reduced risk of clinically significant worsening by 54% (p=0.0037) on CDR-SB at 32 weeks.
- In patients with minimal AD co-pathology (ptau181<2.2), risk reduction improved to 64% (p=0.0001).
- Significant decrease in plasma GFAP biomarker: -18.4 pg/mL from baseline in active group vs +1.1 pg/mL increase in placebo at Week 16.
- Plans to meet FDA in Q4 2025 to align on Phase 3 trial design; Phase 3 initiation mid-2026 subject to funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/0001437749-25-025814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/crvo20250808_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer